Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SinoMab BioScience Limited 中國抗體製藥有限公司 (Incorporated in Hong Kong with limited liability) (Stock code: 3681)

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 12 JUNE 2023

Reference is made to the circular (the "Circular") and the notice of annual general meeting (the "Notice of 2023 AGM") dated 27 April 2023 of SinoMab BioScience Limited (the "Company"). Unless the content otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

## POLL RESULTS OF THE 2023 AGM

At the 2023 AGM, all the proposed resolutions as set out in the Notice of 2023 AGM were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended 31 December 2022.	530,249,783 (99.999981%)	100 (0.000019%)
2(a).	To re-elect Mr. George William Hunter CAUTHERLEY as an independent non-executive director of the Company.	530,249,783 (99.999981%)	100 (0.000019%)
2(b).	To re-elect Dr. Haigang CHEN as a non-executive director of the Company.	530,249,783 (99.999981%)	100 (0.000019%)
2(c).	To re-elect Mr. Xun DONG as a non-executive director of the Company.	530,249,783 (99.999981%)	100 (0.000019%)
2(d).	To re-elect Mr. Dylan Carlo TINKER as an independent non-executive director of the Company.	530,249,783 (99.999981%)	100 (0.000019%)
2(e).	To authorise the board of directors to fix the respective directors' remuneration.	530,249,783 (99.999981%)	100 (0.000019%)

		Number of Votes (%)	
Ordinary Resolutions		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of directors to fix its remuneration.	530,249,783 (99.999981%)	100 (0.000019%)
4.	To give a general mandate to the directors of the Company to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of the passing of this resolution.	530,249,783 (99.999981%)	100 (0.000019%)
5.	To give a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of the passing of this resolution.	530,249,783 (99.999981%)	100 (0.000019%)
6.	To extend the general mandate granted to the directors of the Company to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company under the general mandate in Resolution (4).	530,249,783 (99.999981%)	100 (0.000019%)
	nore than 50% of the votes were cast in favour of each e resolutions were duly passed as Ordinary Resolutions.	of the resolutions	numbered 1 to 6
Special Resolution		Number of Votes (%)	
		For	Against
7.	To approve the proposed amendments to the Articles of Association of the Company and the adoption of the Second Amended and Restated Articles of Association	530,249,783 (99.999981%)	100 (0.000019%)

As more than 75% of the votes were cast in favour of resolution numbered 7, the resolution was duly passed as a Special Resolution.

\* The above percentages are rounded to the nearest six decimal places.

Notes:

of the Company.

(a) The full text of the above resolutions numbered 4 to 7 were set out in the Notice of 2023 AGM.

- (b) As at the date of the 2023 AGM, the total number of shares of the Company in issue was 1,034,920,400 shares.
- (c) The total number of shares of the Company entitling the holders to attend and vote on all the resolutions at the 2023 AGM was 1,034,920,400 shares.
- (d) There were no shares entitling the holders to attend and abstain from voting in favour of any of the resolutions at the 2023 AGM as set out in rule 13.40 of the Listing Rules.

- (e) None of the shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions at the 2023 AGM.
- (f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the 2023 AGM.
- (g) The Company's share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the poll taken at the 2023 AGM.
- (h) All Directors attended the 2023 AGM in person or by electronic means.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 June 2023

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the nonexecutive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.